Alkermes plc. Restructuring Charges
Alkermes plc. (ALKS) reported Restructuring Charges of $6.00 million for the 3-month period ending 2023-12-31, per its 10-K filed 2024-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-02-21
- Alkermes plc. restructuring charges for the quarter ending 2023-12-31 was $6.00M.
- Alkermes plc. restructuring charges for the quarter ending 2023-09-30 was $6.00M.
- Alkermes plc. restructuring charges for the quarter ending 2019-12-31 was $13.40M.
- Alkermes plc. restructuring charges for the quarter ending 2013-09-30 was $0.00.
- Alkermes plc. restructuring charges for fiscal 2023 was $5.97M.
- Alkermes plc. restructuring charges for fiscal 2019 was $13.40M.
| Period end | Restructuring Charges | Restructuring Charges 1 month | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $6.00M 10-K · filed 2024-02-21 | $12.00M derived: sum of 2 quarters · filed 2024-02-21 | $5.97M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $6.00M 10-Q · filed 2023-10-25 | $5.97M 10-Q · filed 2023-10-25 | ||||
| 2019-12-31 | $13.40M 10-K · filed 2022-02-16 | $13.40M 10-K · filed 2022-02-16 | ||||
| 2019-10-31 | $13.40M 10-Q · filed 2020-10-29 | |||||
| 2019-10-18 | $13.40M 10-K · filed 2021-02-11 | |||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | $0.00 derived: sum of 2 quarters · filed 2014-10-29 | $12.30M 10-Q · filed 2014-10-29 | |||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $12.30M 10-Q · filed 2014-07-31 | ||||
| 2013-03-31 | $12.30M 10-Q · filed 2014-04-30 | $12.30M 10-Q · filed 2015-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |